Virus-like Particle Vaccine for Feline Panleukopenia: Immunogenicity and Protective Efficacy in Cats
Vaccines · 25.06.2025 · 13 (7) · 684
DOI: 10.3390/vaccines13070684 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 25.06.2025. Verfasst von Tongyan Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Feline panleukopenia, caused by FPV, is a highly contagious disease in cats. Current vaccines face challenges including complex production, high cost, and safety risks. Developing safer, more efficient alternatives is crucial. This study aimed to produce FPV virus-like particles (VLPs) using a recombinant baculovirus system expressing the VP2 gene and evaluate their immunogenicity and protective efficacy in cats.
Methods
Sf9 insect cells were infected with recombinant baculovirus to express VP2 protein. The VP2 protein was purified using ultrafiltration and size-exclusion chromatography (SEC). Dynamic light scattering (DLS) and transmission electron microscopy (TEM) confirmed the assembly of VLPs. Twenty healthy cats were randomly divided into four groups; three groups received different doses (5 μg, 15 μg, and 45 μg) of FPV VLP vaccine, while the fourth group served as the control group immunized with PBS. Blood samples were collected on day 21 to measure hemagglutination inhibition (HI) and virus-neutralizing (VN) antibody responses. Cats in the 15 μg dose group were challenged with virulent FPV strain 708 on day 21, and clinical signs and white blood cell counts were monitored for 10 days.
Results
Immunized cats exhibited significantly higher HI and VN antibody titers compared to controls. After challenge, vaccinated cats showed no clinical signs of disease, and their white blood cell counts remained stable. In contrast, control cats developed severe symptoms and experienced significant leukopenia.
Conclusions
The FPV VLP vaccine generated in this study are highly immunogenic and provide effective protection against virulent FPV challenge, demonstrating their potential as a safer vaccine candidate for feline panleukopenia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China.
- National Research Center for Veterinary Medicine, Road Cuiwei, High-Tech District, Luoyang 471003, China.
- Pulike Biological Engineering, Inc., Luoyang 471000, China.
Zitieren
APA
Wang, T., Wu, H., Wang, Y., Guan, Y., Cao, Y., Wang, L., Wang, M., Tan, F., Pang, W., & Tian, K. (2025). Virus-like Particle Vaccine for Feline Panleukopenia: Immunogenicity and Protective Efficacy in Cats. Vaccines, 13(7), 684. https://doi.org/10.3390/vaccines13070684
Vancouver
Wang T, Wu H, Wang Y, Guan Y, Cao Y, Wang L, et al. Virus-like Particle Vaccine for Feline Panleukopenia: Immunogenicity and Protective Efficacy in Cats. Vaccines. 2025;13(7):684. doi:10.3390/vaccines13070684
BibTeX
@article{Wang2025,
author = {Wang, Tongyan and Wu, Hongchao and Wang, Yanwei and Guan, Yang and Cao, Yujiao and Wang, Lulu and Wang, Mengyue and Tan, Feifei and Pang, Wenqiang and Tian, Kegong},
title = {Virus-like Particle Vaccine for Feline Panleukopenia: Immunogenicity and Protective Efficacy in Cats},
journal = {Vaccines},
year = {2025},
volume = {13},
number = {7},
pages = {684},
doi = {10.3390/vaccines13070684}
}
EUVIMED